Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.
Breast Cancer Res Treat
; 188(1): 21-36, 2021 Jul.
Article
in En
| MEDLINE
| ID: mdl-34115243
Key words
Anthracyclines; Breast cancer; CRCD; Cardiotoxicity; Chemotherapy; Chemotherapy-related cardiac dysfunction; Congestive heart failure; Echocardiography; Global longitudinal strain; HER2; Herceptin; Kadcyla; LVEF; Lapatinib; Left ventricular ejection fraction; Margetuximab; Neratinib; Perjeta; Pertuzumab; T-DM1; TIC; Taxanes; Trastuzumab; Trastuzumab deruxtecan; Trastuzumab emtansine; Trastuzumab-induced cardiotoxicity; Tucatinib
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Cardiotoxicity
Type of study:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Female
/
Humans
Language:
En
Journal:
Breast Cancer Res Treat
Year:
2021
Document type:
Article
Affiliation country:
Estados Unidos
Country of publication:
Países Bajos